Biogen Idec Inc 

BIIB:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
235.24 2.62   1.13%0.00%825,8791.3M

Market data is delayed by at least 20 minutes.
  •  
    Advanced Charts

  •  
    Embed Chart

    Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

  • 1 Day
  • 5 Day
  • 6 Mo
  • 1 Yr
  • 5 Yr
Market is closed. As of 03:59 PM ET 5/24/2013
 
 
 

Latest News Headlines for Biogen Idec Inc

Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
1 days 21 hours 20 minutes ago - BusinessWire via Dow Jones News
-- Addition of Renowned Scientist Underscores Commitment to Vibrant and Innovative Scientific Research -- WESTON, Mass.--(BUSINESS WIRE)--May 23, 2013-- Biogen Idec (NASDAQ:BIIB) today announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the company's Chief Scientific Officer (CSO). Dr. Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School. He will now continue in this role in a permanent capacity, and will also lead the company's research strategy, capabilities and discovery platforms. Dr. Artavanis-Tsakonas will report to Doug Williams, Executive Vice President of Research and Development. He will continue to serve as a Professor of Cell Biology at Harvard Medical School, where he was the founding Director of the Developmental and Regenerative Biology graduate program.
Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
2 days 13 hours 19 minutes ago - BusinessWire via Dow Jones News
WESTON, Mass.--(BUSINESS WIRE)--May 22, 2013-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference. The webcast will be live on Thursday, May 30, 2013 at 12:00 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY(TM) (Peginterferon Beta-1a) in Multiple Sclerosis
4 days 50 minutes ago - BusinessWire via Dow Jones News
-- EMA Submission Planned in the Coming Weeks -- WESTON, Mass.--(BUSINESS WIRE)--May 21, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY(TM) (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 5, 2013
This report contains detailed information about the company's business finances and management.
10-Q
April 25, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
230.87
Previous Close
232.62
Day High
235.40
Day Low
229.35
52wk High/Date
238.83 / 5/22/2013
52wk Low/Date
126.39 / 6/4/2012
% off 52wk High
-1.50%
% off 52wk Low
86.12%
Beta (5 Yr)
0.9
Market Capitalization
55.8B
Shares Outstanding
237.4M
Volatility Avg
23.83
EPS(TTM)
6.30
P/E Ratio
37.4x
Dividend Announcement
--
Dividend Yield
0.00%
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 5/24/2013 4:00 PM ET
 
 
 

BIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
60.72%
Pfizer Inc.
15.79%
BIIB
Biogen Idec Inc
0.00%
Pfizer Inc.
3.31%
BIIB
Biogen Idec Inc
1.13%
Pfizer Inc.
-0.24%
Compare these stocks